Histone deacetylase inhibitors enhance estrogen receptor beta expression and augment agonist-mediated tumor suppression in glioblastoma.
Uday P PratapGangadhara R SareddyZexuan LiuPrabhakar Pitta VenkataJunhao LiuWeiwei TangKristin A AltweggBehnam EbrahimiXiaonan LiRajeshwar R TekmalSuryavathi ViswanadhapalliStanton McHardyAndrew J BrennerRatna K VadlamudiPublished in: Neuro-oncology advances (2021)
Our results suggest that the combination therapy of HDACi and LY500307 provides therapeutic utility in overcoming the suppression of ERβ expression that commonly occurs in GBM progression.